Tomivosertib

Tomivosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against MAP kinase-interacting serine/threonine-protein kinase 2 and MAP kinase-interacting serine/threonine-protein kinase 1. In addition, it is known to target serine/threonine-protein kinase 17A and dual specificity protein kinase CLK4.